Juan Segura-Aguilar
Overview
Explore the profile of Juan Segura-Aguilar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
6675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huenchuguala S, Segura-Aguilar J
Antioxidants (Basel)
. 2024 Sep;
13(9).
PMID: 39334784
Recently, a single-neuron degeneration model has been proposed to understand the development of idiopathic Parkinson's disease based on (i) the extremely slow development of the degenerative process before the onset...
2.
Huenchuguala S, Segura-Aguilar J
Biomolecules
. 2024 Jun;
14(6).
PMID: 38927076
One of the biggest problems in the treatment of idiopathic Parkinson's disease is the lack of new drugs that slow its progression. L-Dopa remains the star drug in the treatment...
3.
Huenchuguala S, Segura-Aguilar J
Biomedicines
. 2023 Nov;
11(11).
PMID: 38002094
The transition metal characteristics of iron allow it to play a fundamental role in several essential aspects of human life such as the transport of oxygen through hemoglobin or the...
4.
Huenchuguala S, Segura-Aguilar J
Neural Regen Res
. 2023 Sep;
19(3):529-535.
PMID: 37721280
The positive effect of levodopa in the treatment of Parkinson's disease, although it is limited in time and has severe side effects, has encouraged the scientific community to look for...
5.
Huenchuguala S, Segura-Aguilar J
Cell Mol Life Sci
. 2023 Sep;
80(10):281.
PMID: 37688601
No abstract available.
6.
Segura-Aguilar J, Mannervik B
Antioxidants (Basel)
. 2023 Mar;
12(3).
PMID: 36978921
Investigations of the effect of antioxidants on idiopathic Parkinson's disease have been unsuccessful because the preclinical models used to propose these clinical studies do not accurately represent the neurodegenerative process...
7.
De Araujo F, Frota A, de Jesus L, Cuenca-Bermejo L, Ferreira K, Santos C, et al.
Neurotox Res
. 2023 Feb;
41(3):224-241.
PMID: 36723781
Causes of dopaminergic neuronal loss in Parkinson's disease (PD) are subject of investigation and the common use of models of acute neurodegeneration induced by neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine, and rotenone...
8.
Santos C, Cardim-Pires T, Shvachiy L, Fonseca-Fonseca L, Munoz P, Almeida A, et al.
Neurotox Res
. 2022 Aug;
40(6):2135-2147.
PMID: 35997936
Studies showed that JM-20, a benzodiazepine-dihydropyridine hybrid molecule, protects against rotenone and 6-hydroxydopamine neurotoxicity. However, its protective effects against cytotoxicity induced by endogenous neurotoxins involved in Parkinson's disease (PD) pathogenesis...
9.
Segura-Aguilar J, Munoz P, Inzunza J, Varshney M, Nalvarte I, Mannervik B
Antioxidants (Basel)
. 2022 Feb;
11(2).
PMID: 35204179
Glutathione is an important antioxidant that plays a crucial role in the cellular protection against oxidative stress and detoxification of electrophilic mutagens, and carcinogens. Glutathione transferases are enzymes catalyzing glutathione-dependent...
10.
Segura-Aguilar J, Mannervik B, Inzunza J, Varshney M, Nalvarte I, Munoz P
Neural Regen Res
. 2022 Feb;
17(9):1861-1866.
PMID: 35142659
Astrocytes protect neurons by modulating neuronal function and survival. Astrocytes support neurons in several ways. They provide energy through the astrocyte-neuron lactate shuttle, protect neurons from excitotoxicity, and internalize neuronal...